Al Ameen Journal of Medical Sciences (Jul 2013)
Endoscopic treatment of vesicoureteral reflux with dextranomer/ hyaluronic acid-our experience
Abstract
Objectives: We report our experience with subureteral submucosal injection therapy for vesicoureteral reflux and determine the safety and efficacy in patients treated with dextranomer/ hyaluronic acid co-polymer. Background: Vesicoureteral reflux affects 1% of children and increases the chances of urinary tract infection, pyelonephritis, hypertension and chronic renal insufficiency. The aim of identifying and treating vesicoureteral reflux in children is to prevent occurrence of long term complications. Method: A total of sixty three patients aged between 1-21 years with grade III – V vesicoureteral reflux, who had failed on conservative treatment were considered for this study during February 2004 to May 2012.Vesicoureteral reflux was diagnosed by voiding cysto-urethrogram (VCUG). They underwent subureteral injection of dextranomer/ hyaluronic acid co-polymer. Results: Among the sixty three patients treated, 51(81%) were cured with single injection while a second injection raised the cure rate to 60(95%). Conclusion: The minimally invasive treatment of vesicoureteral reflux with deflux (dextranomer/ hyaluronic acid co-polymer) is an effective alternative procedure to open surgical technique requiring minimal operating time with low morbidity.
